Focus of Study
Conditions
Brief summary
This randomized, open label, parallel-group study is designed to investigate whether periprocedural intensive statin therapy with atorvastatin versus rosuvastatin administration before PCI and 30-day continuous intensive treatment is superior to usual care, in terms of cardiovascular events for Chinese elderly patients.
Detailed description
1800 elderly patients (\>65 yr) with coronary artery disease undergoing elective PCI were randomized in 2:1 fashion into either intensive statin group or standard care group. Patients in intensive statin group is further randomized into two subgroups: administrated with either atorvastatin 80mg 12h prior PCI, then 40mg 2h prior PCI, followed by 40 mg/d for 30 days after PCI; or rosuvastatin 20mg 12h prior PCI, then 10mg 2h prior PCI; followed by 10 mg/d for 30 days after PCI, while the standard care group receives atorvastatin 20 mg/d. After angiography, patients who are not undergoing PCI procedure will be excluded from the study as selection failure. The last visit will be at 6 months after PCI. Clinical data such as troponin, CK-MB, Scr, CCR, ALT, AST before and 24h to 48h after procedure will be recorded. 1000 eligible patients will be finally enrolled.The study will be conducted at 12 centers in China.
Interventions
DRUGAtorvastatin
DRUGRosuvastatin
Sponsors
Beijing Anzhen Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
65-80 years old Patients undergoing for elective percutaneous coronary intervention Evidence of a personally signed and dated informed consent document
Exclusion criteria
* Patients undergoing emergency percutaneous coronary intervention * Taking or, needing to take atorvastatin over than 20mg/d or any other equivalent statin (such as simvastatin 20mg/d, pruvastatin 40mg/d, fluvastatin 80mg/d or rovastatin 5mg/d ) in the next 6 months, or needing to take fibrates or niacins simultaneously according to investigators' judgment. * LDL-C \< 1.8mmol/L in patients without statin therapy * Endstage congestive heart failure, or LVEF \< 30% * Active hepatic disease or hepatic dysfunction, or AST/ALT \> 1.5UNL * Myopathy or increased creatine kinase (CK\>2 UNL) * WBC \< 4×109/L or PLT \< 100×109/L * Severe renal dysfunction(Scr \> 3 mg/dl or 264μmol/L) * Allergic or experienced serious adverse reaction to HMG-CoA reductase, or ineligible to take statin as investigator's judgment * Severe aortic valve stenosis or severe mitral stenosis, Obstructive hypertrophic cardiomyopathy, pericardial diseases * Accompanied with malignant disease or other disease, which cause life expectancy \< 6 months * Participating in other interventional clinical trials using drugs or devices * Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 30-day MACCEs after PCI | 30-day after PCI | 30-day major adverse cardio- and cerebralvascular events (combined endpoints of cardiac death, myocardial infarction, stroke, stent thrombosis and target vessel revascularization ) after PCI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| changes in myocardial biomarkers (troponin I, Creatine kinase-MB) | 24 hours after PCI | changes in myocardial biomarkers (troponin I, Creatine kinase-MB) |
Countries
China
Contacts
Primary ContactFei Gao, MD
Outcome results
None listed